Five Prime Therapeutics (FPRX) Announces Proposed 5M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Five Prime Therapeutics (FPRX) Halted on LUDP
November 11, 2020 9:48 AM ESTFive Prime Therapeutics (NASDAQ: FPRX) Halted on LUDP
Pre-Open Stock Movers 11/11: (FPRX) (FUBO) (SURF) Higher; (EGAN) (ACB) (MODN) Lower (more...)
November 11, 2020 9:29 AM ESTToday's Pre-Open Stock Movers:
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) ) 293% HIGHER; announced positive topline results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial. The trial compared mFOLFOX6 chemotherapy in combination with bemarituzumab (bema, FPA144), a first-in-class targeted therapy, in patients with fibroblast growth factor receptor 2b-positive (FGFR2b+), non HER2 positive (non HER2+) front-line advanced gastric or gastroesophageal junction (GEJ) cancer.
eGain (NASDAQ: EGAN) 27.7% LOWER; Total revenue was $19.1 million, up 11% year over... More
Roth Capital Upgrades Five Prime Therapeutics (FPRX) to Buy
November 11, 2020 8:09 AM ESTRoth Capital analyst Tony Butler upgraded Five Prime Therapeutics (NASDAQ: FPRX) from Neutral to Buy with a price target of $30.00.
For an analyst ratings summary and ratings history on Five Prime Therapeutics... More
Wells Fargo Upgrades Five Prime Therapeutics (FPRX) to Overweight
November 11, 2020 4:38 AM ESTWells Fargo analyst Jim Birchenough upgraded Five Prime Therapeutics (NASDAQ: FPRX) from Equal Weight to Overweight with a price target of $34.00.
For an analyst ratings summary and ratings history on Five Prime Therapeutics... More
UPDATE: JPMorgan Upgrades Five Prime Therapeutics (FPRX) to Neutral
November 11, 2020 4:38 AM EST(Updated - November 11, 2020 6:05 AM EST)
(updating comment)
JPMorgan analyst Eric Joseph upgraded Five Prime Therapeutics (NASDAQ: FPRX) from Underweight to Neutral with a price target of $14.00.
The analyst comments "We are rated Neutral on FPRX shares. With encouraging... More
Five Prime Therapeutics (FPRX) Surges Over 250% on Positive Bemarituzumab Results
November 10, 2020 5:38 PM ESTFive Prime Therapeutics (NASDAQ: FPRX) is surging 255% after-hours after it... More
Five Prime Therapeutics (FPRX) Halted, News Pending
November 10, 2020 4:01 PM ESTFive Prime Therapeutics (NASDAQ: FPRX) Halted, News Pending
